Luke Miels
Coverage of Luke Miels in the Nexus archive.
- STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
GSK CEO Luke Miels announced a three-year cost-cutting plan targeting 1.9 billion pounds in annual savings by 2029, with funds reinvested into late-stage drug trials. The company aims to increase Phase 3 trials from 10 to 20 this year, focusing on areas like oncology, liver disease, vaccines, and HIV.
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker GSK, led by new CEO Luke Miels, has agreed to acquire US-based cancer treatment firm Nuvalent for $10.6 billion. The deal aims to strengthen GSK's oncology portfolio, with Nuvalent developing three late-stage lung cancer medications.
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker GSK has agreed to acquire US-based cancer treatment company Nuvalent for $10.6 billion to expand its oncology portfolio. The deal includes Nuvalent's three late-stage lung cancer medications.
- GSK reports promising early results in ovarian and womb cancer drug trial
GSK reported early trial results showing Mo-Rez reduced or eliminated tumors in 62% of ovarian cancer patients and 67% of endometrial cancer patients. The CEO, Luke Miels, is advancing drug development efforts for the potential blockbuster treatment.